RESUMEN
Objective To evaluate the efficacy of surgery,chemotherapy and surgery combined chemotherapy for retinoblastoma(RB),and analyze the prognostic factors of RB patients.Methods Clinical data of 1188 RB patients registered in the Surveillance,Epidemiology and End Results(SEER)database from January 2000 to December 2019 were retrospectively analyzed.The baseline characteristics of patients treated with surgery,chemotherapy or surgery combined with chemotherapy were balanced by inverse probability of treatment weighting(IPTW).Log-rank test analysis was used to compare the survival probability of patients in the 3 groups,and Cox regression models were used to analyse the factors influencing the prognosis of RB patients.Results A total of 1188 RB cases were included in this study,including 426 cases in surgery group,200 cases in chemotherapy group and 562 cases in surgery combined with chemotherapy group.After IPTW weighting,baseline data such as age,sex and race were balanced(P>0.05).Log-rank test results showed that the survival curves of the three groups were significantly different before and after weighting(P<0.05).After weighted,the survival of patients in surgery group was significantly better than that in chemotherapy group and surgery combined chemotherapy group(P<0.05),and there was no statistical significance between chemotherapy group and surgery combined chemotherapy group(P>0.05).The weighted patient survival probability at 1st,3rd and 5th years were 99.7%,98.9%and 98.6%in surgery group;97.4%,95.8%and 95.8%in chemotherapy group;and 97.9%,95.8%and 95.0%in surgery combined chemotherapy group.Cox regression analysis showed that compared with surgery group,the specific risk ratio of death was 1.367(95%CI 1.100-1.700)in chemotherapy group and 1.132(95%CI 0.963-1.330)in combined chemotherapy group.Compared with patients with 1 RB lesion,the patient-specific mortality risk ratio for patients with 2 or more RB lesions was 0.399(95%CI 0.268-0.594).Conclusions Patients with RB have higher survival rates probability after treatment.After controlling the influence of age,sex and other factors,the effect of surgery was better among the three treatment methods.Multifocality may be an independent prognostic factor in RB patients.
RESUMEN
Due to its complex pathogenesis and lack of effective therapeutic methods, Alzheimer's disease (AD) has become a severe public health problem worldwide. Recent studies have discovered the function of central nervous system lymphatic drainage, which provides a new strategy for the treatment of AD. Chinese herbal medicine (CHM) has been considered as a cure for AD for hundreds of years in China, and its effect on scavenging β-amyloid protein in the brain of AD patients has been confirmed. In this review, the mechanism of central nervous system lymphatic drainage and the regulatory functions of CHM on correlation factors were briefly summarized. The advances in our understanding regarding the treatment of AD via regulating the central lymphatic system with CHM will promote the clinical application of CHM in AD patients and the discovery of new therapeutic drugs.
Asunto(s)
Humanos , Enfermedad de Alzheimer/tratamiento farmacológico , Péptidos beta-Amiloides , Encéfalo , China , Medicamentos Herbarios Chinos/uso terapéuticoRESUMEN
ObjectiveTo observe the effect of Linggui Zhugantang (LG) on the blood-brain barrier (BBB) model of Alzheimer's disease (AD) in vitro and to explore the mechanism of LG in repairing the BBB injury in AD. MethodA total of 50 male SPF rats were randomized into five groups: high-dose (4.8 g·kg-1), medium-dose (2.4 g·kg-1), and low-dose (1.2 g·kg-1) LG groups, western medicine (0.5 g·kg-1 donepezil hydrochloride) group, and normal group (normal saline of equivalent volume). They received (ig) corresponding drugs twice a day for 7 d. Drug-containing serum was respectively collected from the abdominal aorta 1 h after the last administration. The BBB injury of AD in vitro was induced with the cell co-culture method, and 6 groups were designed: normal group, model group, high-, medium-, and low-dose LG groups, and western medicine group. The model group was added with 100 μL amyloid β1-42 (Aβ1-42, final concentration: 5 μmol·L-1), and high-dose, medium-dose, and low-dose LG groups and the western medicine group were added with corresponding 10% drug-containing serum in addition to the 100 μL Aβ1-42 (final concentration: 5 μmol·L-1). Cell survival rate was detected by methyl thiazolyl tetrazolium (MTT) assay, expression of BBB-related skeleton proteins (claudin-5, ZO-1, occludin), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) by Western blot, and content of inflammatory factors interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) by enzyme-linked immunosorbent assay (ELISA). BBB Aβ transporter low-density lipoprotein receptor-related protein 1 (LRP-1) and advanced glycation end product receptor (RAGE) at different time points in high-dose, medium-dose, and low-dose LG groups were determined by Real-time PCR and Western blot. ResultCell survival rate of the model group was lower than that of the normal group (P<0.05) and the survival rates of the western medicine group and high-dose LG group was higher than that in the model group (P<0.05). The skeleton proteins were down-regulated and MMP-2 and MMP-9 were up-regulated in the model group compared with those in the normal group (P<0.05). The expression of skeleton proteins was higher (P<0.05) and that of MMP-2 and MMP-9 was lower (P<0.05) in the western medicine group and high-dose LG group than in the model group. Compared with the model group, only the medium-dose LG group showed the up-regulation (P<0.05) of claudin-5 (P<0.05) and the decrease (P<0.05) of MMP-2. IL-1β, IL-6, and TNF-α in the model group were up-regulated (P<0.05) compared with those in the normal group, and those inflammatory factors in the western medicine group and high-dose and medium-dose LG groups were lower (P<0.05) than those in the model group. LRP-1 expression was up-regulated and RAGE expression was down-regulated at 3 h compared with those at 0 h (P<0.05), while the expression of the two became stable at 6, 12, 24, 36 h. At 3 h, LRP-1 expression was down-regulated and RAGE expression was up-regulated in model group compared with those in the normal group at 3 h (P<0.05). Moreover, the LRP-1 content was higher and RAGE content was lower in the western medicine group and high-dose LG group than in the model group. ConclusionLG can repair the BBB injury in vitro by inhibiting the expression of inflammatory factors and MMP-2, MMP-9, promoting the expression of skeletal proteins, and regulating the balance of transporters.